Bladder Cancer Comparison Study Design

> Research explainer: This briefing examines verified primary research published 70 days before the briefing date. It is not a same-day research update and does not provide medical advice.

Evidence

The Surgery or Radiotherapy for early-stage cancer (SORT) study is a protocol for an observational comparative-effectiveness and cost-effectiveness study in organ-confined muscle-invasive bladder cancer (OC-MIBC). It will compare radical radiotherapy with radical cystectomy when each follows neoadjuvant chemotherapy (NAC). The protocol defines the study population as people with urothelial OC-MIBC staged T2–4aN0M0 who were diagnosed in England from 1 January 2015 through 31 December 2021 and received NAC followed by one of those definitive treatments. [pmid:42276804]

The clinical question reflects a stated evidence gap. The protocol says an earlier randomized controlled trial intended to compare these approaches after NAC did not recruit successfully. It also describes prior observational comparisons as vulnerable to substantial confounding and notes that many included people who had not received NAC. Those background observations motivate SORT’s design; they are not results from SORT itself. [pmid:42276804]

SORT plans to identify eligible individuals in the English National Cancer Registry and link those records with Hospital Episode Statistics, the National Radiotherapy Data Set, and Systemic Anti-Cancer Therapy data. The stated purpose of the linked data is to assemble information on clinical, tumour, sociodemographic, and treatment characteristics. [pmid:42276804]

The prespecified primary outcome is all-cause mortality three years after receipt of radical treatment. Secondary planned outcomes include all-cause mortality and bladder-cancer-associated mortality at three and five years, time to death, incremental costs, and incremental cost-effectiveness expressed through net health benefits. [pmid:42276804]

Analysis — Study Design and Evidence Gap

This source is most useful as an explanation of what evidence SORT intends to generate and why its methods matter. It does not report a treatment comparison. A future estimate from the study would depend on how well the emulated target-trial framework and statistical adjustment account for differences between people receiving radiotherapy and those receiving cystectomy. The protocol states that these methods will be used to reduce bias from measured baseline differences, which is a central challenge when treatment allocation was not randomized. [pmid:42276804]

The design deliberately narrows the comparison to people who received NAC before definitive treatment. That restriction addresses a limitation the authors identify in earlier observational literature, where inclusion of people without NAC complicated interpretation. It also makes the planned question more specific: outcomes and costs after NAC followed by radical radiotherapy versus NAC followed by radical cystectomy in the defined English registry population. [pmid:42276804]

Linkage across registry, hospital, radiotherapy, and systemic-treatment data may allow the planned analyses to describe treatment receipt and relevant recorded characteristics more completely than a single dataset could. Yet richer linkage does not turn routine data into randomized evidence. The protocol explicitly acknowledges that unobserved baseline differences may remain, including differences related to staging after NAC, particularly among people receiving radical radiotherapy. Therefore, even a carefully analyzed observational comparison would require interpretation in light of residual confounding. [pmid:42276804]

The protocol also places cost-effectiveness alongside mortality and time-to-death outcomes. That scope is important because the stated evidence gap concerns both comparative clinical effectiveness and relative cost-effectiveness after NAC. However, the protocol’s list of planned outcomes is not evidence that either treatment is less costly, more cost-effective, or associated with better survival. Those questions remain unanswered by this source. [pmid:42276804]

Limitations

This briefing is constrained to one study protocol published on 11 June 2026. No SORT comparative-effectiveness, mortality, cost, or cost-effectiveness results are reported. Consequently, the source does not establish that radical radiotherapy and radical cystectomy have similar, superior, or inferior outcomes after NAC. [pmid:42276804]

The protocol’s discussion of earlier studies is background rather than a new analysis, and its account should not be read as an independent validation of those earlier findings. The planned study is also limited to England, diagnoses from 2015–2021, urothelial T2–4aN0M0 disease, and recipients of NAC followed by one of the two radical treatments. Any eventual findings would need to be considered within that population and healthcare setting. Finally, the authors identify potential unobserved baseline differences as a limitation of the observational design. [pmid:42276804]